160. 先天性魚鱗癬 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 57 / 薬物数 : 68 - (DrugBank : 25) / 標的遺伝子数 : 21 - 標的パスウェイ数 : 141
薬物、開発者(Primary Sponsor)、臨床試験情報(症例登録開始年(Enrollment year)、フェーズ、ID、実施国)
1643368-58-4
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2017 Phase 2 EUCTR2016-000101-37-IT Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
Bristol-Myers Squibb International Corporation
2017 Phase 2 EUCTR2016-000101-37-GR Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
Abatacept
Bristol-Myers Squibb International Corporation
2017 Phase 3 EUCTR2016-001948-19-SE Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
2016 Phase 3 EUCTR2016-001948-19-FR Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
2016 Phase 3 EUCTR2016-001948-19-CZ Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
Active topical NS2 1% dermatologic cream
Aldeyra Therapeutics, Inc.
2015 Phase 2 NCT02402309 United States
Adalimumab
Assistance Publique - Hôpitaux de Paris
2014 Phase 2 NCT02113904 France
ADX-629
University of Nebraska
2023 Phase 1/Phase 2 NCT05443685 United States
ANTI-CD28DAB
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2017 Phase 2 EUCTR2016-000101-37-IT Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
Bristol-Myers Squibb International Corporation
2017 Phase 2 EUCTR2016-000101-37-GR Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
Apply veregen ® 10 % ON A randomized area and THE moisturizing cream OF THE other side
Centre Hospitalier Universitaire de Nice
2010 Phase 3 NCT01222000 France
Atorvastatin
Department of Dermatology, Keio University School of Medicine
2013 - JPRN-UMIN000012355 Japan
Kubo Akiharu
2013 Phase 2 JPRN-jRCTs031180409 -
ATR12-351
Azitra Inc.
2024 Phase 1 NCT06137157 United States
BCX17725
BioCryst Pharmaceuticals
2024 Phase 1 NCT06539507 Australia
Bezafibrate
2011 - EUCTR2011-001205-27-NL Netherlands
Bezalip retard
2011 - EUCTR2011-001205-27-NL Netherlands
BMS-188667
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2017 Phase 3 EUCTR2016-001948-19-IT Argentina;Australia;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
Bristol-Myers Squibb International Corporation
2017 Phase 3 EUCTR2016-001948-19-SE Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
2016 Phase 3 EUCTR2016-001948-19-FR Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
2016 Phase 3 EUCTR2016-001948-19-CZ Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
BMS-931699
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2017 Phase 2 EUCTR2016-000101-37-IT Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
Bristol-Myers Squibb International Corporation
2017 Phase 2 EUCTR2016-000101-37-GR Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
BMS-986142
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2017 Phase 2 EUCTR2016-000101-37-IT Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
Bristol-Myers Squibb International Corporation
2017 Phase 2 EUCTR2016-000101-37-GR Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
BMS986142
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2017 Phase 2 EUCTR2016-000101-37-IT Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
Bristol-Myers Squibb International Corporation
2017 Phase 2 EUCTR2016-000101-37-GR Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
BPR277
Novartis Pharma Services AG
2013 - EUCTR2011-000917-38-NL France;Germany;Netherlands;United States
2011 - EUCTR2011-000917-38-DE France;Germany;Netherlands;United States
BPR277 ointment
Novartis Pharmaceuticals
2011 Phase 1 NCT01428297 France;Germany;Netherlands;United States
BTK inhibitor
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2017 Phase 2 EUCTR2016-000101-37-IT Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
Bristol-Myers Squibb International Corporation
2017 Phase 2 EUCTR2016-000101-37-GR Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
Cholesterol
Department of Dermatology, Keio University School of Medicine
2013 - JPRN-UMIN000012355 Japan
Kubo Akiharu
2013 Phase 2 JPRN-jRCTs031180409 -
CNT-02
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
2016 - NCT02830763 Italy;Japan
Deucravacitinib
Centre Hospitalier Universitaire de Nice
2023 Phase 2 NCT06136403 France
DS-2325A
Daiichi Sankyo
2023 Phase 1/Phase 2 NCT05979831 France
Daiichi Sankyo, Inc.
2022 Phase 1 NCT05583669 United States
2022 Phase 1 NCT05388903 United States
Dupilumab
CHU de Toulouse
2019 Phase 2 EUCTR2019-001220-35-FR France
Dupilumab injection
National Medical Research Center for Children's Health, Russian Federation
2021 Phase 4 NCT04996485 Russian Federation
Dupilumab prefilled syringe
University Hospital, Toulouse
2020 Phase 2/Phase 3 NCT04244006 France
Dupixent
CHU de Toulouse
2019 Phase 2 EUCTR2019-001220-35-FR France
Epithelial sheet generated from transduced autologous keratinocytes using PCCL-INVO-SP
GOSH/ICH Joint Research & Development Office
2013 Phase 1 EUCTR2011-003212-22-GB United Kingdom
Erlotinib
Northwestern University
2025 Phase 1/Phase 2 NCT06545695 United States
Fibrate treatment
Maastricht University Medical Center
2011 Phase 4 NCT01527318 Netherlands
Hematopoetic stem cell transplantation
University of Pittsburgh
2012 - NCT03333200 United States
Humira
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2013 - EUCTR2013-002205-54-FR France
Isotretinoin
Timber Pharmceuticals LLC
2019 Phase 2 NCT04154293 Australia;United States
Isotretinoina
Timber Pharmaceuticals, Inc
2022 Phase 3 EUCTR2022-000459-35-IT Canada;France;Germany;Italy;United States
Ixekizumab
Dermatology Hospital of Southern Medical University
2022 Phase 2 ChiCTR2200059272 China
KB105
Krystal Biotech, Inc.
2023 Phase 2 NCT05735158 United States
2019 Phase 1/Phase 2 NCT04047732 United States
L04ab04
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2013 - EUCTR2013-002205-54-FR France
Lipoxygenase inhibitor
UMC St Radboud
2009 Phase 3 EUCTR2009-015895-87-NL Netherlands
Lovastatin
Northwestern University
2011 Phase 2 NCT01110642 United States
Monolaurin cream
Cellegy Pharmaceuticals
1996 Phase 3 NCT00004690 -
ONE 20cm2/10cm2 autologous skin sheet graft
Great Ormond Street Hospital for Children NHS Foundation Trust
2014 Phase 1 NCT01545323 United Kingdom
Oral glucose tolerance test
University Hospital, Toulouse
2015 - NCT02383316 France
Orencia
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2017 Phase 3 EUCTR2016-001948-19-IT Argentina;Australia;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
Bristol-Myers Squibb International Corporation
2017 Phase 3 EUCTR2016-001948-19-SE Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
2016 Phase 3 EUCTR2016-001948-19-FR Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
2016 Phase 3 EUCTR2016-001948-19-CZ Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
Oxiconazole
Department of Dermatology, Keio University School of Medicine
2013 - JPRN-UMIN000012355 Japan
Kubo Akiharu
2013 Phase 2 JPRN-jRCTs031180409 -
Palliative care
University of Pittsburgh
2012 - NCT03333200 United States
PAT
Patagonia Pharmaceuticals, LLC
2017 Phase 2 NCT02864082 United States
Pimecrolimus 1% cream
Children's Hospital of Philadelphia
2005 Phase 1/Phase 2 NCT00208026 United States
PRE-filled syringe
Bristol-Myers Squibb International Corporation
2017 Phase 3 EUCTR2016-001948-19-SE Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
2016 Phase 3 EUCTR2016-001948-19-FR Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
2016 Phase 3 EUCTR2016-001948-19-CZ Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
QRX003, 4% lotion
Quoin Pharmaceuticals
2025 Phase 2/Phase 3 NCT06953466 United States
2023 Phase 2/Phase 3 NCT05789056 United States
QRX003-2% lotion
Quoin Pharmaceuticals
2022 Phase 2/Phase 3 NCT05521438 United States
QRX003-4% lotion BID
Quoin Pharmaceuticals
2022 Phase 2/Phase 3 NCT05521438 United States
QRX003-4% lotion QAM
Quoin Pharmaceuticals
2022 Phase 2/Phase 3 NCT05521438 United States
Reproxalap
Aldeyra Therapeutics, Inc.
2018 Phase 3 NCT03445650 United States
RVG 18388
2011 - EUCTR2011-001205-27-NL Netherlands
SAR231893
CHU de Toulouse
2019 Phase 2 EUCTR2019-001220-35-FR France
Secukinumab
Northwestern University
2016 Phase 2 NCT03041038 United States
Secukinumab injection
National Medical Research Center for Children's Health, Russian Federation
2021 Phase 4 NCT04996485 Russian Federation
Simvastatin
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
2020 Phase 0 ChiCTR2000037278 China
Spesolimab
Taguchi Aya
2023 Phase 2-3 JPRN-jRCT2031220722 Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Finland;France;Germany;Israel;Italy;Japan;Malaysia;Netherlands;Portugal;Spain;Switzerland;United Kingdom;United States
Spesolimab - solution FOR infusion
Boehringer Ingelheim
2023 Phase 2/Phase 3 NCT05856526 Australia;Austria;Belgium;Bulgaria;China;Finland;France;Germany;Israel;Italy;Japan;Malaysia;Netherlands;Portugal;Switzerland;United Kingdom;United States
Spesolimab - solution FOR injection
Boehringer Ingelheim
2023 Phase 2/Phase 3 NCT05856526 Australia;Austria;Belgium;Bulgaria;China;Finland;France;Germany;Israel;Italy;Japan;Malaysia;Netherlands;Portugal;Switzerland;United Kingdom;United States
SXR1096
Sixera Pharma
2022 Phase 1;Phase 2 EUCTR2021-003210-39-AT Austria;Finland;Germany;Sweden
2021 Phase 1;Phase 2 EUCTR2021-003210-39-FI Finland
- Phase 1;Phase 2 EUCTR2021-003210-39-SE Austria;Finland;Germany;Sweden
- Phase 1;Phase 2 EUCTR2021-003210-39-DE Austria;Finland;Germany
Symptomatic therapy
National Medical Research Center for Children's Health, Russian Federation
2021 Phase 4 NCT04996485 Russian Federation
TMB-001
Timber Pharmaceuticals, Inc
2022 Phase 3 EUCTR2022-000459-35-IT Canada;France;Germany;Italy;United States
Timber Pharmaceuticals, LLC
2022 Phase 3 EUCTR2022-000459-35-FR Austria;Canada;France;Germany;Italy;Spain;United States
- Phase 3 EUCTR2022-000459-35-DE Canada;France;Germany;Italy;United States
Ustekinumab injection
National Medical Research Center for Children's Health, Russian Federation
2021 Phase 4 NCT04996485 Russian Federation
Vehicle
Aldeyra Therapeutics, Inc.
2015 Phase 2 NCT02402309 United States
Novartis Pharmaceuticals
2011 Phase 1 NCT01428297 France;Germany;Netherlands;United States
Patagonia Pharmaceuticals, LLC
2017 Phase 2 NCT02864082 United States
Quoin Pharmaceuticals
2022 Phase 2/Phase 3 NCT05521438 United States
Timber Pharmceuticals LLC
2019 Phase 2 NCT04154293 Australia;United States
Vehicle OF ADX-102 topical dermal cream
Aldeyra Therapeutics, Inc.
2018 Phase 3 NCT03445650 United States
Zileuton
UMC St Radboud
2009 Phase 3 EUCTR2009-015895-87-NL Netherlands
Zyflo CR
UMC St Radboud
2009 Phase 3 EUCTR2009-015895-87-NL Netherlands
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2017 Phase 2 EUCTR2016-000101-37-IT Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
Bristol-Myers Squibb International Corporation
2017 Phase 2 EUCTR2016-000101-37-GR Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
Abatacept
Bristol-Myers Squibb International Corporation
2017 Phase 3 EUCTR2016-001948-19-SE Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
2016 Phase 3 EUCTR2016-001948-19-FR Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
2016 Phase 3 EUCTR2016-001948-19-CZ Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
Active topical NS2 1% dermatologic cream
Aldeyra Therapeutics, Inc.
2015 Phase 2 NCT02402309 United States
Adalimumab
Assistance Publique - Hôpitaux de Paris
2014 Phase 2 NCT02113904 France
ADX-629
University of Nebraska
2023 Phase 1/Phase 2 NCT05443685 United States
ANTI-CD28DAB
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2017 Phase 2 EUCTR2016-000101-37-IT Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
Bristol-Myers Squibb International Corporation
2017 Phase 2 EUCTR2016-000101-37-GR Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
Apply veregen ® 10 % ON A randomized area and THE moisturizing cream OF THE other side
Centre Hospitalier Universitaire de Nice
2010 Phase 3 NCT01222000 France
Atorvastatin
Department of Dermatology, Keio University School of Medicine
2013 - JPRN-UMIN000012355 Japan
Kubo Akiharu
2013 Phase 2 JPRN-jRCTs031180409 -
ATR12-351
Azitra Inc.
2024 Phase 1 NCT06137157 United States
BCX17725
BioCryst Pharmaceuticals
2024 Phase 1 NCT06539507 Australia
Bezafibrate
2011 - EUCTR2011-001205-27-NL Netherlands
Bezalip retard
2011 - EUCTR2011-001205-27-NL Netherlands
BMS-188667
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2017 Phase 3 EUCTR2016-001948-19-IT Argentina;Australia;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
Bristol-Myers Squibb International Corporation
2017 Phase 3 EUCTR2016-001948-19-SE Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
2016 Phase 3 EUCTR2016-001948-19-FR Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
2016 Phase 3 EUCTR2016-001948-19-CZ Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
BMS-931699
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2017 Phase 2 EUCTR2016-000101-37-IT Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
Bristol-Myers Squibb International Corporation
2017 Phase 2 EUCTR2016-000101-37-GR Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
BMS-986142
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2017 Phase 2 EUCTR2016-000101-37-IT Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
Bristol-Myers Squibb International Corporation
2017 Phase 2 EUCTR2016-000101-37-GR Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
BMS986142
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2017 Phase 2 EUCTR2016-000101-37-IT Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
Bristol-Myers Squibb International Corporation
2017 Phase 2 EUCTR2016-000101-37-GR Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
BPR277
Novartis Pharma Services AG
2013 - EUCTR2011-000917-38-NL France;Germany;Netherlands;United States
2011 - EUCTR2011-000917-38-DE France;Germany;Netherlands;United States
BPR277 ointment
Novartis Pharmaceuticals
2011 Phase 1 NCT01428297 France;Germany;Netherlands;United States
BTK inhibitor
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2017 Phase 2 EUCTR2016-000101-37-IT Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
Bristol-Myers Squibb International Corporation
2017 Phase 2 EUCTR2016-000101-37-GR Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
Cholesterol
Department of Dermatology, Keio University School of Medicine
2013 - JPRN-UMIN000012355 Japan
Kubo Akiharu
2013 Phase 2 JPRN-jRCTs031180409 -
CNT-02
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
2016 - NCT02830763 Italy;Japan
Deucravacitinib
Centre Hospitalier Universitaire de Nice
2023 Phase 2 NCT06136403 France
DS-2325A
Daiichi Sankyo
2023 Phase 1/Phase 2 NCT05979831 France
Daiichi Sankyo, Inc.
2022 Phase 1 NCT05583669 United States
2022 Phase 1 NCT05388903 United States
Dupilumab
CHU de Toulouse
2019 Phase 2 EUCTR2019-001220-35-FR France
Dupilumab injection
National Medical Research Center for Children's Health, Russian Federation
2021 Phase 4 NCT04996485 Russian Federation
Dupilumab prefilled syringe
University Hospital, Toulouse
2020 Phase 2/Phase 3 NCT04244006 France
Dupixent
CHU de Toulouse
2019 Phase 2 EUCTR2019-001220-35-FR France
Epithelial sheet generated from transduced autologous keratinocytes using PCCL-INVO-SP
GOSH/ICH Joint Research & Development Office
2013 Phase 1 EUCTR2011-003212-22-GB United Kingdom
Erlotinib
Northwestern University
2025 Phase 1/Phase 2 NCT06545695 United States
Fibrate treatment
Maastricht University Medical Center
2011 Phase 4 NCT01527318 Netherlands
Hematopoetic stem cell transplantation
University of Pittsburgh
2012 - NCT03333200 United States
Humira
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2013 - EUCTR2013-002205-54-FR France
Isotretinoin
Timber Pharmceuticals LLC
2019 Phase 2 NCT04154293 Australia;United States
Isotretinoina
Timber Pharmaceuticals, Inc
2022 Phase 3 EUCTR2022-000459-35-IT Canada;France;Germany;Italy;United States
Ixekizumab
Dermatology Hospital of Southern Medical University
2022 Phase 2 ChiCTR2200059272 China
KB105
Krystal Biotech, Inc.
2023 Phase 2 NCT05735158 United States
2019 Phase 1/Phase 2 NCT04047732 United States
L04ab04
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2013 - EUCTR2013-002205-54-FR France
Lipoxygenase inhibitor
UMC St Radboud
2009 Phase 3 EUCTR2009-015895-87-NL Netherlands
Lovastatin
Northwestern University
2011 Phase 2 NCT01110642 United States
Monolaurin cream
Cellegy Pharmaceuticals
1996 Phase 3 NCT00004690 -
ONE 20cm2/10cm2 autologous skin sheet graft
Great Ormond Street Hospital for Children NHS Foundation Trust
2014 Phase 1 NCT01545323 United Kingdom
Oral glucose tolerance test
University Hospital, Toulouse
2015 - NCT02383316 France
Orencia
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2017 Phase 3 EUCTR2016-001948-19-IT Argentina;Australia;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
Bristol-Myers Squibb International Corporation
2017 Phase 3 EUCTR2016-001948-19-SE Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
2016 Phase 3 EUCTR2016-001948-19-FR Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
2016 Phase 3 EUCTR2016-001948-19-CZ Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
Oxiconazole
Department of Dermatology, Keio University School of Medicine
2013 - JPRN-UMIN000012355 Japan
Kubo Akiharu
2013 Phase 2 JPRN-jRCTs031180409 -
Palliative care
University of Pittsburgh
2012 - NCT03333200 United States
PAT
Patagonia Pharmaceuticals, LLC
2017 Phase 2 NCT02864082 United States
Pimecrolimus 1% cream
Children's Hospital of Philadelphia
2005 Phase 1/Phase 2 NCT00208026 United States
PRE-filled syringe
Bristol-Myers Squibb International Corporation
2017 Phase 3 EUCTR2016-001948-19-SE Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
2016 Phase 3 EUCTR2016-001948-19-FR Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
2016 Phase 3 EUCTR2016-001948-19-CZ Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
QRX003, 4% lotion
Quoin Pharmaceuticals
2025 Phase 2/Phase 3 NCT06953466 United States
2023 Phase 2/Phase 3 NCT05789056 United States
QRX003-2% lotion
Quoin Pharmaceuticals
2022 Phase 2/Phase 3 NCT05521438 United States
QRX003-4% lotion BID
Quoin Pharmaceuticals
2022 Phase 2/Phase 3 NCT05521438 United States
QRX003-4% lotion QAM
Quoin Pharmaceuticals
2022 Phase 2/Phase 3 NCT05521438 United States
Reproxalap
Aldeyra Therapeutics, Inc.
2018 Phase 3 NCT03445650 United States
RVG 18388
2011 - EUCTR2011-001205-27-NL Netherlands
SAR231893
CHU de Toulouse
2019 Phase 2 EUCTR2019-001220-35-FR France
Secukinumab
Northwestern University
2016 Phase 2 NCT03041038 United States
Secukinumab injection
National Medical Research Center for Children's Health, Russian Federation
2021 Phase 4 NCT04996485 Russian Federation
Simvastatin
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
2020 Phase 0 ChiCTR2000037278 China
Spesolimab
Taguchi Aya
2023 Phase 2-3 JPRN-jRCT2031220722 Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Finland;France;Germany;Israel;Italy;Japan;Malaysia;Netherlands;Portugal;Spain;Switzerland;United Kingdom;United States
Spesolimab - solution FOR infusion
Boehringer Ingelheim
2023 Phase 2/Phase 3 NCT05856526 Australia;Austria;Belgium;Bulgaria;China;Finland;France;Germany;Israel;Italy;Japan;Malaysia;Netherlands;Portugal;Switzerland;United Kingdom;United States
Spesolimab - solution FOR injection
Boehringer Ingelheim
2023 Phase 2/Phase 3 NCT05856526 Australia;Austria;Belgium;Bulgaria;China;Finland;France;Germany;Israel;Italy;Japan;Malaysia;Netherlands;Portugal;Switzerland;United Kingdom;United States
SXR1096
Sixera Pharma
2022 Phase 1;Phase 2 EUCTR2021-003210-39-AT Austria;Finland;Germany;Sweden
2021 Phase 1;Phase 2 EUCTR2021-003210-39-FI Finland
- Phase 1;Phase 2 EUCTR2021-003210-39-SE Austria;Finland;Germany;Sweden
- Phase 1;Phase 2 EUCTR2021-003210-39-DE Austria;Finland;Germany
Symptomatic therapy
National Medical Research Center for Children's Health, Russian Federation
2021 Phase 4 NCT04996485 Russian Federation
TMB-001
Timber Pharmaceuticals, Inc
2022 Phase 3 EUCTR2022-000459-35-IT Canada;France;Germany;Italy;United States
Timber Pharmaceuticals, LLC
2022 Phase 3 EUCTR2022-000459-35-FR Austria;Canada;France;Germany;Italy;Spain;United States
- Phase 3 EUCTR2022-000459-35-DE Canada;France;Germany;Italy;United States
Ustekinumab injection
National Medical Research Center for Children's Health, Russian Federation
2021 Phase 4 NCT04996485 Russian Federation
Vehicle
Aldeyra Therapeutics, Inc.
2015 Phase 2 NCT02402309 United States
Novartis Pharmaceuticals
2011 Phase 1 NCT01428297 France;Germany;Netherlands;United States
Patagonia Pharmaceuticals, LLC
2017 Phase 2 NCT02864082 United States
Quoin Pharmaceuticals
2022 Phase 2/Phase 3 NCT05521438 United States
Timber Pharmceuticals LLC
2019 Phase 2 NCT04154293 Australia;United States
Vehicle OF ADX-102 topical dermal cream
Aldeyra Therapeutics, Inc.
2018 Phase 3 NCT03445650 United States
Zileuton
UMC St Radboud
2009 Phase 3 EUCTR2009-015895-87-NL Netherlands
Zyflo CR
UMC St Radboud
2009 Phase 3 EUCTR2009-015895-87-NL Netherlands